The PNPLA3 rs3810622 intron variant has been previously reported to be associated with elevated alanine aminotransferase and blood glucose32 and decreased serum triglyceride in NAFLD patients, suggesting its role in MAFLD as well as NAFLD33,34. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.